Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
2020 · Journal of Thoracic Oncology · 399 citations
https://doi.org/10.1016/j.jtho.2020.01.017
J
Jie Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
640
Papers
18.0K
Citations
57
h-index
235
i10-index
Jie Wang is an academic researcher from Qiqihar University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 57, co-authored 544 publications.
ORCID: 0000-0002-5602-0487Papers by this author
worksCirculating cell-free DNA for cancer early detection
2022 · The Innovation · 146 citations
https://doi.org/10.1016/j.xinn.2022.100259
Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer
2022 · Signal Transduction and Targeted Therapy · 138 citations
https://doi.org/10.1038/s41392-022-01150-4
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial
2024 · Nature Medicine · 109 citations
https://doi.org/10.1038/s41591-024-03132-1
The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
2020 · European Journal of Nuclear Medicine and Molecular Imaging · 87 citations
https://doi.org/10.1007/s00259-020-04711-3
Gut microbial taxa as potential predictive biomarkers for acute coronary syndrome and post-STEMI cardiovascular events
2020 · Scientific Reports · 78 citations
https://doi.org/10.1038/s41598-020-59235-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat